Teva Pharmaceuticals USA, Inc. recalls 21,984 packages of Isotretinoin Capsules, USP, 30 mg. The lots are distributed to Florida, Ohio, Puerto Rico and Mississippi. The recall is active as of April 15, 2026.
Superpotent and Subpotent
Consumers and healthcare providers should stop using this product immediately. Contact Teva Pharmaceuticals USA, Inc or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Isotretinoin capsules are prescribed for severe acne when other treatments fail. The 30 mg dose comes in 10-count prescription packs manufactured for Teva. These are distributed to several states and territories.
Potency variations can lead to underdosing or overdosing, impacting safety and efficacy. Serious birth defects risk remains for pregnant patients exposed to isotretinoin.
This recall is not described as part of a broader safety pattern in the provided data.
Patients may need physician oversight to adjust dose. No injuries are reported in the data, but potency inconsistency can result in treatment failure or adverse effects.
Recall notices and lot-specific guidance are on the FDA enforcement page and Teva recall communications.
Refunds or replacements guided by Teva recall communications; typically weeks to months depending on pharmacy/provider processing.
Keep the recall letter, lot numbers, expiration dates, pharmacy records, and any physician communications for your records.
Product: Isotretinoin Capsules, USP, 30 mg, Rx Only, 10 count Prescription Pack. Manufactured for Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054. NDC 0591-2435-15 (carton), NDC 0591-2435-45 (blister). Generic: Isotretinoin. Brand: Isotretinoin. Quantity: 21,984 packages. Distribution: FL, OH, PR, MS. Status: Active recall as of 2026-01-12. Company contact: Teva Pharmaceuticals USA, Inc.
No specific injuries or incidents are listed in the provided data. The FDA enforcement page notes classification and distribution details, but does not enumerate injuries.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Teva-affiliated Clonidine Transdermal System recalls 113,943 cartons after CGMP deviations. Unapproved raw material prompts recall. Stop use immediately and contact Teva or a healthcare provider for guidance.
Teva Pharmaceuticals recalled 124,054 cartons of Clonidine Transdermal System due to CGMP deviations from an unapproved raw material. The recall affects products sold in the United States. Consumers should stop using the product immediately and consult a healthcare provider for guidance.
Teva Pharmaceuticals recalled 67,043 bottles of Metoprolol Succinate Extended-Release Tablets, 50 mg, distributed nationwide. The FDA enforcement report cites Failed Dissolution Specifications as the hazard. Health care providers and patients should stop using this product immediately and contact Teva for guidance.
Teva Pharmaceuticals USA, Inc. recalls 8,376 isotretinoin 40 mg capsules distributed to FL, OH, PR and MS after FDA enforcement report flags superpotent and subpotent lots. Patients should stop use and contact their healthcare providers for guidance.
Actavis Laboratories recalled 15,944 cartons of Testosterone Gel on November 7, 2025. The recall follows a defect in the side-seal of the containers, which may allow product leakage. Consumers must stop using the product immediately and contact their healthcare providers for guidance.